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In most European countries, regulatory agencies are engaged
in approving reimbursement schemes for the new interferon-free
direct antiviral agents (DAAs) for hepatitis C.1 2 The degree of
reimbursement differs across countries and sometimes between
regions of the same country.
Owing to budget constraints, most national approvals for
reimbursement have been restricted to patients with more severe
disease, according to ethical and clinical considerations.2-5
In May 2015, the Tuscany region of Italy proposed a regional
tendering scheme that extended reimbursement to about 20 000
patients with milder disease.6 This tender will probably close
over the next month.
This project has been debated among institutions, politicians,
patient associations, scientific societies, and experts in the field.3
Opponents (such as the Italian Medicines Agency4) argue that
the proposal is not pharmaceutically sustainable; another
criticism is that the effectiveness of newer DAAs relies on a
surrogate endpoint with no information on long term effects;
finally, trying to eradicate this disease locally has been
questioned on theoretical grounds. Ethics has been advocated
by all stakeholders, but ethics seems to support both prioritising
patients with severe disease and ensuring that those with milder,
but potentially progressive, disease are treated. The American
Association of the Liver recently recommended treating all
hepatitis C infected people except those with a life expectancy
of less than 12 months due to unrelated conditions.7
Patients’ associations initially argued that extended coverage
in one region only would be an infringement of equity but now
recognise that it might pave the way for other regions to follow.
It is unprecedented for an effective treatment not to be used in
patients with mild disease for economic reasons. The cure rate
is high in mild disease, so eradicating the disease in these cases
would save healthcare costs and prevent onward transmission.
Reducing drug costs by increasing competition between
manufacturers could be a solution. At its first run, the Tuscan
tender set a maximum treatment cost per patient of about one
tenth of the drug’s full price, but at the second run no such limit
will be applied.6 The results of the Tuscan tender are eagerly
awaited by scientists, clinicians, and patients.
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